Business Context and Reporting Period
This Form 6-K filing by Prana Biotechnology Limited (not Alteryx Therapeutics Ltd as indicated in metadata) covers the quarter ended December 31, 2016, and the six-month period ending on that date. The registrant is an Australian biotechnology entity subject to ASX Listing Rule 4.7B.
Key Financial Metrics
| Metric | Current Quarter ($A'000) | Year to Date ($A'000) |
|---|---|---|
| Receipts from Customers | 0 | 0 |
| Net Cash from Operating Activities | 1,749 | (748) |
| Net Cash from Investing Activities | 0 | (4) |
| Net Cash from Financing Activities | (46) | (46) |
| Cash and Cash Equivalents (End of Period) | 28,342 | 28,342 |
| Government Grants and Tax Incentives | 4,754 | 4,754 |
| Staff Costs | (689) | (1,335) |
| Research and Development Costs | (1,654) | (3,216) |
The filing does not provide revenue, profit, or margin figures as the company reported zero receipts from customers. Debt and liquidity are reflected in the cash balance of $28.3 million with no drawn loan facilities.
Material Changes
- Cash Position: Cash and cash equivalents increased significantly to $28.3 million at quarter-end, driven primarily by a $4.75 million government grant and tax incentive received during the period.
- Operating Cash Flow: The current quarter showed a positive operating cash flow of $1.75 million, contrasting with a negative $748,000 for the six-month year-to-date period.
- Revenue: No revenue was recognized from customers in either the current quarter or the year-to-date period.
Outlook, Risks, and Commentary
Estimated Cash Outflows: Management estimates total cash outflows for the next quarter to be $3.7 million, with the majority allocated to research and development ($2.3 million) and staff costs ($689,000).
Financing: The company has no drawn loan facilities or credit standby arrangements. Financing activities were limited to transaction costs of $46,000 related to share issues.
Risks: The company remains in a pre-revenue stage with significant reliance on government grants and existing cash reserves to fund operations and R&D.
Investor Verification Checklist
- Verify the nature and sustainability of the $4.75 million government grant received.
- Confirm the company's runway given the estimated $3.7 million cash outflow for the upcoming quarter against current cash reserves.
- Review the status of research and development programs consuming $3.2 million over the last six months.
- Check for any pending capital raises, as no new share proceeds were recorded in this period.